Koch Dominik Thomas, Schirren Malte, Jacobi Severin, Lange Christian, Werner Jens, Koliogiannis Dionysios, Guba Markus
Department of General, Visceral and Transplant Surgery, LMU University Hospital, LMU, Munich, Germany.
Department of Internal Medicine II, LMU University Hospital, LMU, Munich, Germany.
Contemp Clin Trials Commun. 2025 Feb 22;44:101465. doi: 10.1016/j.conctc.2025.101465. eCollection 2025 Apr.
A substantial number of viable donor livers are discarded due to the donor's underlying malignancy. Concurrently, patients with certain liver malignancies - such as unresectable colorectal cancer liver metastases (CRC-LM), unresectable intrahepatic or perihilar cholangiocarcinoma (iCCC/phCCC), or unresectable hepatocellular carcinoma (HCC) responding to immunotherapy - often face poor survival outcomes and are deemed ineligible for potentially curative liver transplantation. In this context, a rational risk-benefit analysis suggests that transplanting an organ with a theoretical risk of tumor transmission may be justifiable for these patients facing otherwise short-term fatal outcomes.
The TRANSMIT study is a compassionate use exploratory study aimed at assessing the utility and safety of using donor organs from individuals with a current or past history of cancer for liver transplantation in patients with liver malignancies (CRC-LM, i/phCCC, HCC) who are not eligible for regular organ allocation. The study will evaluate the utilization rate of donor organs that would otherwise be discarded, overall survival, progression-free survival, and tumor transmission rates at one and three years, stratified by indication.
Donor organs from individuals with a current or past history of cancer may represent a valuable and safe resource for expanding the limited donor pool, particularly for patients who lack access to standard organ allocation.
相当数量的活体供肝因供体潜在的恶性肿瘤而被丢弃。与此同时,患有某些肝脏恶性肿瘤的患者——如无法切除的结直肠癌肝转移(CRC-LM)、无法切除的肝内或肝门周围胆管癌(iCCC/phCCC),或对免疫疗法有反应的无法切除的肝细胞癌(HCC)——往往面临较差的生存结局,被认为不符合潜在治愈性肝移植的条件。在这种情况下,合理的风险效益分析表明,对于这些面临短期致命结局的患者,移植具有理论上肿瘤传播风险的器官可能是合理的。
TRANSMIT研究是一项同情用药探索性研究,旨在评估将有当前或既往癌症病史个体的供体器官用于不符合常规器官分配条件的肝脏恶性肿瘤(CRC-LM、i/phCCC、HCC)患者肝移植的效用和安全性。该研究将评估否则会被丢弃的供体器官的利用率、总生存期、无进展生存期以及1年和3年时的肿瘤传播率,并按适应症分层。
有当前或既往癌症病史个体的供体器官可能是扩大有限供体库的宝贵且安全的资源,特别是对于那些无法获得标准器官分配的患者。